Financials & Growth
The acquisition of Affinivax by GSK was one of the biggest deals of the industry in 2022
Affinivax was one of LabCentral's first resident companies and grew alongside us as we expanded our model throughout the years. We are elated to celebrate this massive achievement with them and look forward to seeing their novel technology advance the life sciences and better human health.
"We were one of the first residents at LabCentral. We started with a suite with no equipment and no staff. As we matured, LabCentral helped us with our growing pains and we greatly appreciated what LabCentral was doing in the background so we could stay focused on our own growth and mission.
I would highly recommend LabCentral to young life sciences companies for two reasons. One is it's established, it's there. All the stuff you need to worry about, it's done. LabCentral takes care of the operational burden so you can stay focused on hiring the right people and testing your science.
The second thing is I can't describe enough how special this communty is when you're trying to build a young company. Biotechs need to be in Cambridge, specifically Kendall Square, and LabCentral is an adaptive and established model ready to set you up for success on day one."
BIGGEST PHARMA DEAL IN 2022
LABCENTRAL CAPTURED $1.197B OF EARLY-STAGE FUNDING IN BIOPHARMA
THAT’S 21% OF THE TOTAL EARLY-STAGE BIOPHARMA MARKET IN THE US IN 2022
AND 35% OF THE EARLY-STAGE BIOPHARMA MARKET IN MA
Of the 10 largest Series A in biotech in 2022, 4 were LabCentral residents.
Similarly, of the 8 IPOs of MA-based biotech, 1 was from LabCentral.
Growth & Alumni Access
In 2022, we opened Phase II of LabCentral 238 and The Blavatnik Harvard Life Lab, adding a combined 60,000 square feet of operational lab space. This growth was strategically aligned to meet the needs of LabCentral’s resident companies for scale-up biomanufacturing process development, in addition to providing additional opportunities for companies at the earliest stages of growth.
In 2022 LabCentral Had:
LabCentral creates opportunities that empower innovators by building community. The novelty of the technologies developed within our walls is reflected year over year by the number of patents granted, clinical trials conducted, and patients dosed.